Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,568 | 232 | 1,333 |
| Samples | 556 | 115 | 440 |
| Peptides | 418 | 71 | 360 |
Function
CDH17 · Cadherin 17
This gene is a member of the cadherin superfamily, genes encoding calcium-dependent, membrane-associated glycoproteins. The encoded protein is cadherin-like, consisting of an extracellular region, containing 7 cadherin domains, and a transmembrane region but lacking the conserved cytoplasmic domain. The protein is a component of the gastrointestinal tract and pancreatic ducts, acting as an intestinal proton-dependent peptide transporter in the first step in oral absorption of many medically important peptide-based drugs. The protein may also play a role in the morphological organization of liver and intestine. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2009].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 398 amino-acid changes on canonical ENST00000027335 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDH17 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDH17 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 18/210 9% | 110/1899 6% |
| Endometrial Carcinoma | 3/42 7% | 27/612 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 22/304 7% | 29/1390 2% |
| Other Solid Cancers | 2/94 2% | 35/1515 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Bladder Carcinoma | 2/58 3% | 17/956 2% |
| Colorectal Carcinoma | 14/143 10% | 44/3239 1% |
| Neuroendocrine Tumour | 7/154 5% | 5/577 1% |
| Gastric Carcinoma | 3/74 4% | 20/1809 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 10/810 1% |
| Hepatocellular Carcinoma | 4/46 9% | 21/2210 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Other Sarcomas | 2/69 3% | 4/699 1% |
| Breast Carcinoma | 8/144 6% | 18/3264 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Ovarian Carcinoma | 0/109 0% | 8/998 1% |
| Biliary Tract Carcinoma | 3/54 6% | 3/950 0% |
| Glioma | 0/52 0% | 13/2127 1% |
| Head and Neck Carcinoma | 1/85 1% | 8/1574 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 6/1592 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Prostate Carcinoma | 3/13 23% | 6/2105 0% |
Mutation Distribution
Where CDH17 is mutated · all tissues, split by cell line vs tissue
How many mutations in CDH17 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,568 mutations in CDH17
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|